Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oregovomab - OncoQuest

Next Previous
Drug Profile

Oregovomab - OncoQuest

Alternative Names: Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-CA125; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center; Yonsei University
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Pancreatic cancer

Most Recent Events

  • 20 Jan 2026 Oregovomab is still in the phase III FLORA-5 trial for Fallopian tube cancer (Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA, Argentina, Belgium, Brazil, Canada, Chile, Czech Republic, Hungary, India, Italy, South Korea, Mexico, Poland, Spain, Taiwan and Romania (IV) (NCT04498117)
  • 20 Jan 2026 Oregovomab is still in the phase III FLORA-5 trial for Ovarian cancer (Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA, Argentina, Belgium, Brazil, Canada, Chile, Czech Republic, Hungary, India, Italy, South Korea, Mexico, Poland, Spain, Taiwan and Romania (IV) (NCT04498117)
  • 20 Jan 2026 Oregovomab is still in the phase III FLORA-5 trial for Peritoneal cancer (Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA, Argentina, Belgium, Brazil, Canada, Chile, Czech Republic, Hungary, India, Italy, South Korea, Mexico, Poland, Spain, Taiwan and Romania (IV) (NCT04498117)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top